Latest Clinical Trials
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 18, 2026)
PHASE1 Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease National Cancer Institute (NCI) NA
RECRUITING
(Sep 18, 2026)
PHASE1 Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation National Cancer Institute (NCI) NA
RECRUITING
(Sep 15, 2026)
PHASE1 FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma National Cancer Institute (NCI) NA
RECRUITING
(Sep 10, 2026)
PHASE1 CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia National Cancer Institute (NCI) NA
RECRUITING
(Sep 9, 2026)
PHASE2 Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) National Cancer Institute (NCI) NA
RECRUITING
(Sep 9, 2026)
PHASE1 The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation National Cancer Institute (NCI) NA
RECRUITING
(Sep 4, 2026)
PHASE1, PHASE2 Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate Centre Oscar Lambret NA
COMPLETED
(Sep 1, 2026)
PHASE1 Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL Stichting Hemato-Oncologie voor Volwassenen Nederland NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study European Organisation for Research and Treatment of Cancer - EORTC NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Liver Transplantation With Tregs at MGH National Institute of Allergy and Infectious Diseases (NIAID) NA
COMPLETED
(Sep 1, 2026)
PHASE1, PHASE2 Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma UNC Lineberger Comprehensive Cancer Center NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma UNC Lineberger Comprehensive Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm M.D. Anderson Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma University of Washington NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) Genmab NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Haploidentical HCT for Severe Aplastic Anemia St. Jude Children's Research Hospital NA
RECRUITING
(Sep 1, 2026)
PHASE2 Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Genmab NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies Benjamin Tomlinson NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Diwakar Davar NA
COMPLETED
(Sep 1, 2026)
PHASE2 Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma Genmab NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents Chongqing Precision Biotech Co., Ltd NA
RECRUITING
(Sep 1, 2026)
PHASE2 NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Fred Hutchinson Cancer Center NA
COMPLETED
(Sep 1, 2026)
PHASE1 Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer H. Lee Moffitt Cancer Center and Research Institute NA
SUSPENDED
(Sep 1, 2026)
PHASE1 GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors Grit Biotechnology NA
RECRUITING
(Sep 1, 2026)
PHASE1 The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer Universitas Indonesia NA
RECRUITING
(Sep 1, 2026)
PHASE2 Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL Chinese PLA General Hospital NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Genmab NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer Arsenal Biosciences, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia M.D. Anderson Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC H. Lee Moffitt Cancer Center and Research Institute NA
RECRUITING
(Sep 1, 2026)
PHASE1 Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 NRG Oncology NA
RECRUITING
(Sep 1, 2026)
PHASE3 Cord Blood Transplant in Adults With Blood Cancers Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Hoffmann-La Roche NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors H. Lee Moffitt Cancer Center and Research Institute NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma Regeneron Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma Regeneron Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC UNC Lineberger Comprehensive Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE1 CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 David Porter NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy Cabaletta Bio NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) Autolus Limited NA
RECRUITING
(Sep 1, 2026)
PHASE1 Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma Guangzhou Lupeng Pharmaceutical Company LTD. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients AstraZeneca NA
RECRUITING
(Sep 1, 2026)
PHASE3 ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Leland Metheny NA
SUSPENDED
(Sep 1, 2026)
PHASE2 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML Hemogenyx Pharmaceuticals LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1 Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Roswell Park Cancer Institute NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2 Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood Case Comprehensive Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies M.D. Anderson Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Roswell Park Cancer Institute NA
SUSPENDED
(Sep 1, 2026)
PHASE1 Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population Sung Won Choi NA
RECRUITING
(Sep 1, 2026)
PHASE2 CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas Beijing GoBroad Hospital NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease Allogene Therapeutics NA
RECRUITING
(Sep 1, 2026)
PHASE1 GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults Stanford University NA
RECRUITING
(Sep 1, 2026)
PHASE1 CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas University of Maryland, Baltimore NA
ENROLLING BY INVITATION
(Sep 1, 2026)
PHASE1 CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors Chongqing Precision Biotech Co., Ltd NA
SUSPENDED
(Sep 1, 2026)
PHASE1 Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes H. Lee Moffitt Cancer Center and Research Institute NA
RECRUITING
(Sep 1, 2026)
PHASE1 Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Fred Hutchinson Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE3 Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Paolo Caimi, MD NA
RECRUITING
(Sep 1, 2026)
PHASE1 CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors Baylor College of Medicine NA
WITHDRAWN
(Sep 1, 2026)
PHASE1 A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies Janssen Research & Development, LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis iCell Gene Therapeutics NA
RECRUITING
(Sep 1, 2026)
PHASE2 Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy Kite, A Gilead Company NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies Zelluna Immunotherapy AS NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy AbelZeta Inc. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation Medical College of Wisconsin NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement Pengpeng Xu NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Cardioprotective Effect of Empagliflozin in Breast Cancer Patients Tanta University NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Fred Hutchinson Cancer Center NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Study of C-CAR168 in Participants With Progressive Multiple Sclerosis AbelZeta Inc. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection Corregene Biotechnology Co., Ltd NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC Daping Hospital and the Research Institute of Surgery of the Third Military Medical University NA
COMPLETED
(Sep 1, 2026)
PHASE2 Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer Qingdao Sino-Cell Biomedicine Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis Huashan Hospital NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity Washington University School of Medicine NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia Ruijin Hospital NA
RECRUITING
(Sep 1, 2026)
PHASE1 Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma National Cancer Institute (NCI) NA
RECRUITING
(Aug 24, 2026)
PHASE1 Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas National Cancer Institute (NCI) NA
RECRUITING
(Aug 21, 2026)
PHASE1 A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) National Cancer Institute (NCI) NA
RECRUITING
(Aug 20, 2026)
PHASE1 A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab National Cancer Institute (NCI) NA
RECRUITING
(Aug 18, 2026)
PHASE2 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer National Cancer Institute (NCI) NA
RECRUITING
(Aug 17, 2026)
PHASE2 IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors National Cancer Institute (NCI) NA
NOT YET RECRUITING
(Aug 17, 2026)
PHASE1 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells National Heart, Lung, and Blood Institute (NHLBI) NA
RECRUITING
(Aug 14, 2026)
PHASE2 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer National Cancer Institute (NCI) NA
RECRUITING
(Aug 12, 2026)
PHASE2 T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer National Cancer Institute (NCI) NA
RECRUITING
(Aug 11, 2026)
PHASE2 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers National Cancer Institute (NCI) NA
RECRUITING
(Aug 11, 2026)
PHASE1, PHASE2 Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients National Cancer Institute (NCI) NA
RECRUITING
(Aug 11, 2026)
PHASE1, PHASE2 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer SWOG Cancer Research Network NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer NSABP Foundation Inc NA
COMPLETED
(Aug 1, 2026)
PHASE3 A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia Seattle Children's Hospital NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure National Heart, Lung, and Blood Institute (NHLBI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas Fondazione Italiana Linfomi - ETS NA
COMPLETED
(Aug 1, 2026)
PHASE1, PHASE2 Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation Washington University School of Medicine NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Study on GD2 Positive Solid Tumors by 4SCAR-GD2 Shenzhen Geno-Immune Medical Institute NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Children's Oncology Group NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Combination CAR-T Cell Therapy Targeting Hematological Malignancies Shenzhen Geno-Immune Medical Institute NA
TERMINATED
(Aug 1, 2026)
PHASE1, PHASE2 Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme Shenzhen Geno-Immune Medical Institute NA
TERMINATED
(Aug 1, 2026)
PHASE1 Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis Paul Szabolcs NA
RECRUITING
(Aug 1, 2026)
PHASE2 IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Immune Modulatory DC Vaccine Against Brain Tumor Shenzhen Geno-Immune Medical Institute NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Split-Dose R-CHOP for Older Adults With DLBCL University of Wisconsin, Madison NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors USWM CT, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer ECOG-ACRIN Cancer Research Group NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Jonsson Comprehensive Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Eli Lilly and Company NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 Shenzhen Geno-Immune Medical Institute NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma University College, London NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial National Cancer Institute (NCI) NA
SUSPENDED
(Aug 1, 2026)
PHASE1 A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy Spectrum Pharmaceuticals, Inc NA
RECRUITING
(Aug 1, 2026)
PHASE2 Axi-cel in CNS Lymphoma Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Allogene Therapeutics NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors Baylor College of Medicine NA
RECRUITING
(Aug 1, 2026)
PHASE1 Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma Kite, A Gilead Company NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances M.D. Anderson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances M.D. Anderson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer AstraZeneca NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG DKMS gemeinnützige GmbH NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Mayo Clinic NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies University College, London NA
RECRUITING
(Aug 1, 2026)
PHASE1 KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Christian Hinrichs NA
RECRUITING
(Aug 1, 2026)
PHASE1 CAR T Cells to Target GD2 for DMG University College, London NA
RECRUITING
(Aug 1, 2026)
PHASE1 A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant Ronald Paquette NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation AstraZeneca NA
RECRUITING
(Aug 1, 2026)
PHASE1 Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma M.D. Anderson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 TmPSMA-02 in mCRPC University of Pennsylvania NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE3 Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma M.D. Anderson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma Kite, A Gilead Company NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma AstraZeneca NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus Cabaletta Bio NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE2 Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells Hideho Okada, MD, PhD NA
RECRUITING
(Aug 1, 2026)
PHASE1 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Genmab NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors AstraZeneca NA
RECRUITING
(Aug 1, 2026)
PHASE1 Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies University of Utah NA
RECRUITING
(Aug 1, 2026)
PHASE1 Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Fred Hutchinson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE2 RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis Cabaletta Bio NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis Cabaletta Bio NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. M.D. Anderson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma Malaghan Institute of Medical Research NA
RECRUITING
(Aug 1, 2026)
PHASE2 Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL Allogene Therapeutics NA
RECRUITING
(Aug 1, 2026)
PHASE2 Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma University of Florida NA
RECRUITING
(Aug 1, 2026)
PHASE1 Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma Medical College of Wisconsin NA
RECRUITING
(Aug 1, 2026)
PHASE2 FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia Fred Hutchinson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma USWM CT, LLC NA
COMPLETED
(Aug 1, 2026)
PHASE2 Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(Aug 1, 2026)
PHASE3 Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. Vitebsk Regional Clinical Cancer Centre NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Children's Oncology Group NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma Mayo Clinic NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) Genentech, Inc. NA
WITHDRAWN
(Aug 1, 2026)
PHASE1 Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) Autolus Limited NA
RECRUITING
(Aug 1, 2026)
PHASE2 Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Ohio State University Comprehensive Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Children's National Research Institute NA
RECRUITING
(Aug 1, 2026)
PHASE1 Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma University of Washington NA
RECRUITING
(Aug 1, 2026)
PHASE2 Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial Fred Hutchinson Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 ALL Backbone in AYAs Dana-Farber Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE2 CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma St. Jude Children's Research Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE1 TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT Stanford University NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases Kite, A Gilead Company NA
RECRUITING
(Aug 1, 2026)
PHASE1 B7-H3.CD28Z.CART in Solid Tumors Robbie Majzner NA
RECRUITING
(Aug 1, 2026)
PHASE1 B7-H3.CD28Z.CART in CNS Neoplasms Robbie Majzner NA
RECRUITING
(Aug 1, 2026)
PHASE1 Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma St. Jude Children's Research Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Children's Oncology Group NA
RECRUITING
(Aug 1, 2026)
PHASE3 Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. Arovella Therapeutics Ltd NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers Dispatch Biotherapeutics NA
RECRUITING
(Aug 1, 2026)
PHASE1 Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer Yuan Yuan NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Carrie Ho, MD NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 TCR1188-ABC Cells in KRAS-mutated Cancers University of Pennsylvania NA
RECRUITING
(Aug 1, 2026)
PHASE1 AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") National Cancer Institute (NCI) NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study AIDS Malignancy Consortium NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma Vanderbilt-Ingram Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Liu Shu NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. Juventas Cell Therapy Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1 Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma University College, London NA
RECRUITING
(Aug 1, 2026)
PHASE1 Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma City of Hope Medical Center NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Lazarus: IT Therapy for ICANS Vanderbilt-Ingram Cancer Center NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT AstraZeneca NA
RECRUITING
(Aug 1, 2026)
PHASE3 Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Cellectar Biosciences, Inc. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer Qingdao Sino-Cell Biomedicine Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer Rebecca Arend NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer The Second Hospital of Anhui Medical University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer Fred Hutchinson Cancer Center NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies National Cancer Institute (NCI) NA
RECRUITING
(Jul 28, 2026)
PHASE1, PHASE2 Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 14, 2026)
PHASE1 Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias National Cancer Institute (NCI) NA
RECRUITING
(Jul 14, 2026)
PHASE1, PHASE2 EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection National Cancer Institute (NCI) NA
COMPLETED
(Jul 1, 2026)
PHASE2 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Children's Oncology Group NA
COMPLETED
(Jul 1, 2026)
PHASE3 05-001: Treatment of Acute Lymphoblastic Leukemia in Children Dana-Farber Cancer Institute NA
COMPLETED
(Jul 1, 2026)
PHASE3 Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment UNICANCER NA
COMPLETED
(Jul 1, 2026)
PHASE3 "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer University Health Network, Toronto NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors St. Jude Children's Research Hospital NA
COMPLETED
(Jul 1, 2026)
PHASE2 Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy The Lymphoma Academic Research Organisation NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen Baylor College of Medicine NA
RECRUITING
(Jul 1, 2026)
PHASE1 Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer University of Michigan Rogel Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease University of Illinois at Chicago NA
RECRUITING
(Jul 1, 2026)
PHASE2 Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center NA
TERMINATED
(Jul 1, 2026)
PHASE2 Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment Wake Forest University Health Sciences NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma University of Pennsylvania NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma UNC Lineberger Comprehensive Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Eli Lilly and Company NA
COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) National Cancer Institute (NCI) NA
RECRUITING
(Jul 1, 2026)
PHASE1 Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis Fred Hutchinson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Seagen, a wholly owned subsidiary of Pfizer NA
COMPLETED
(Jul 1, 2026)
PHASE2 Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis Emory University NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 DALY II USA/ MB-CART2019.1 for DLBCL Miltenyi Biomedicine GmbH NA
RECRUITING
(Jul 1, 2026)
PHASE2 GFRα4 CAR T Cells in MTC Patients University of Pennsylvania NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) Kite, A Gilead Company NA
COMPLETED
(Jul 1, 2026)
PHASE2 Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma Celgene NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Hoffmann-La Roche NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Children's Oncology Group NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma University of California, Davis NA
RECRUITING
(Jul 1, 2026)
PHASE1 Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma AIDS Malignancy Consortium NA
RECRUITING
(Jul 1, 2026)
PHASE1 Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors Children's National Research Institute NA
RECRUITING
(Jul 1, 2026)
PHASE1 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Genmab NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors University of California, Irvine NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors Weijia Fang, MD NA
COMPLETED
(Jul 1, 2026)
PHASE1 Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors Chongqing Precision Biotech Co., Ltd NA
COMPLETED
(Jul 1, 2026)
PHASE1 Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Children's Oncology Group NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma University of California, San Francisco NA
TERMINATED
(Jul 1, 2026)
PHASE1 Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors Chongqing Precision Biotech Co., Ltd NA
COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) Boston Children's Hospital NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 CD30 CAR for CD30+ NSGCT UNC Lineberger Comprehensive Cancer Center NA
COMPLETED
(Jul 1, 2026)
PHASE2 Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Fred Hutchinson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC UNICANCER NA
RECRUITING
(Jul 1, 2026)
PHASE2 Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis Nexcella Inc. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children Hee Young Ju NA
RECRUITING
(Jul 1, 2026)
PHASE2 CIML NK Cells With Venetoclax for AML Dana-Farber Cancer Institute NA
RECRUITING
(Jul 1, 2026)
PHASE1 Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas Baylor College of Medicine NA
RECRUITING
(Jul 1, 2026)
PHASE1 Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma Washington University School of Medicine NA
RECRUITING
(Jul 1, 2026)
PHASE1 NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) St. Jude Children's Research Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma OHSU Knight Cancer Institute NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases Nanjing University School of Medicine NA
RECRUITING
(Jul 1, 2026)
PHASE1 Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus Autolus Limited NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells UNC Lineberger Comprehensive Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC Sichuan University NA
RECRUITING
(Jul 1, 2026)
PHASE1 Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma Celgene NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma Celgene NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia Yonsei University NA
RECRUITING
(Jul 1, 2026)
PHASE2 Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma St. Jude Children's Research Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 Outpatient Epcoritamab in Large B-cell Lymphoma Massachusetts General Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease AbelZeta Inc. NA
WITHDRAWN
(Jul 1, 2026)
PHASE1, PHASE2 CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH Beijing GoBroad Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer Second Affiliated Hospital, School of Medicine, Zhejiang University NA
RECRUITING
(Jul 1, 2026)
PHASE2 CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy University of Pennsylvania NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis Genentech, Inc. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma M.D. Anderson Cancer Center NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy Lyell Immunopharma, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE3 Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Hannah Choe, MD NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse National Cancer Institute (NCI) NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Stephan Grupp MD PhD NA
RECRUITING
(Jul 1, 2026)
PHASE1 Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease St. Jude Children's Research Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 The CARDIOPROTECT Trial Beth Israel Deaconess Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation TScan Therapeutics, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE3 GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Massachusetts General Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Dizal Pharmaceuticals NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Jonsson Comprehensive Cancer Center NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy iCell Gene Therapeutics NA
RECRUITING
(Jul 1, 2026)
PHASE1 A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma Ruijin Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers Tata Memorial Centre NA
RECRUITING
(Jul 1, 2026)
PHASE2 Phase II Study of QLC2519 in Pediatric Solid Tumor Participants Qilu Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2 Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients Tata Memorial Centre NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma Weill Medical College of Cornell University NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease Peking Union Medical College Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Iovance Biotherapeutics, Inc. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) Beijing Biotech NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL Changzhou No.2 People's Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL Changzhou No.2 People's Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis National Heart, Lung, and Blood Institute (NHLBI) NA
RECRUITING
(Jun 30, 2026)
PHASE2 Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies National Cancer Institute (NCI) NA
RECRUITING
(Jun 9, 2026)
PHASE1, PHASE2 Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia Seattle Children's Hospital NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL UNC Lineberger Comprehensive Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Mayo Clinic NA
RECRUITING
(Jun 1, 2026)
PHASE1 A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL Versailles Hospital NA
COMPLETED
(Jun 1, 2026)
PHASE2 Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) Medical College of Wisconsin NA
COMPLETED
(Jun 1, 2026)
PHASE2 BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma UNC Lineberger Comprehensive Cancer Center NA
COMPLETED
(Jun 1, 2026)
PHASE2 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid University Hospital, Rouen NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 PG2 Breast Cancer Evaluation in Adjuvant Medicine Study PhytoHealth Corporation NA
COMPLETED
(Jun 1, 2026)
PHASE2 Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes Fred Hutchinson Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma Novartis Pharmaceuticals NA
COMPLETED
(Jun 1, 2026)
PHASE3 Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Fred Hutchinson Cancer Center NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma City of Hope Medical Center NA
SUSPENDED
(Jun 1, 2026)
PHASE1 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University NA
COMPLETED
(Jun 1, 2026)
PHASE2 Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 CAR-T Cell Therapy Targeting to CD19 for R/R ALL The First Affiliated Hospital of Soochow University NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Children's Oncology Group NA
RECRUITING
(Jun 1, 2026)
PHASE3 A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation Dana-Farber Cancer Institute NA
RECRUITING
(Jun 1, 2026)
PHASE1 Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases Fred Hutchinson Cancer Center NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma Centre Hospitalier Universitaire, Amiens NA
COMPLETED
(Jun 1, 2026)
PHASE2 Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma C. Babis Andreadis NA
RECRUITING
(Jun 1, 2026)
PHASE1 ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Fred Hutchinson Cancer Center NA
WITHDRAWN
(Jun 1, 2026)
PHASE1 EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma Baylor College of Medicine NA
RECRUITING
(Jun 1, 2026)
PHASE1 Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma Yazeed Sawalha NA
SUSPENDED
(Jun 1, 2026)
PHASE1 CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Mayo Clinic NA
RECRUITING
(Jun 1, 2026)
PHASE1 Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older The Lymphoma Academic Research Organisation NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma Fondazione Italiana Linfomi - ETS NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 LYL273 for Patients With Relapsed or Refractory mCRC Lyell Immunopharma, Inc. NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer Iovance Biotherapeutics, Inc. NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer David Wald NA
SUSPENDED
(Jun 1, 2026)
PHASE1 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TCR2 Therapeutics NA
TERMINATED
(Jun 1, 2026)
PHASE1, PHASE2 Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma University of Washington NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma City of Hope Medical Center NA
RECRUITING
(Jun 1, 2026)
PHASE1 E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers Christian Hinrichs NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) Takeda NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Christian Hinrichs NA
RECRUITING
(Jun 1, 2026)
PHASE2 Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer M.D. Anderson Cancer Center NA
SUSPENDED
(Jun 1, 2026)
PHASE1, PHASE2 Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL University Health Network, Toronto NA
RECRUITING
(Jun 1, 2026)
PHASE1 Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease St. Jude Children's Research Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations Fred Hutchinson Cancer Center NA
RECRUITING
(Jun 1, 2026)
PHASE1 Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma Elvira Umyarova NA
COMPLETED
(Jun 1, 2026)
PHASE1 Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Kite, A Gilead Company NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 The Lymphoma Academic Research Organisation NA
RECRUITING
(Jun 1, 2026)
PHASE3 Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies M.D. Anderson Cancer Center NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia City of Hope Medical Center NA
SUSPENDED
(Jun 1, 2026)
PHASE1 A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus Hospital for Special Surgery, New York NA
ENROLLING BY INVITATION
(Jun 1, 2026)
PHASE1 R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Phase 2 Study of Rapcabtagene Autoleucel in Myositis Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 US Zamto-cel Autoimmune Diseases Miltenyi Biomedicine GmbH NA
RECRUITING
(Jun 1, 2026)
PHASE1 Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia University of Washington NA
RECRUITING
(Jun 1, 2026)
PHASE2 Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Jun 1, 2026)
PHASE2 Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer Xijing Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma H. Lee Moffitt Cancer Center and Research Institute NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) The University of Texas Health Science Center at San Antonio NA
RECRUITING
(Jun 1, 2026)
PHASE1 RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis Cabaletta Bio NA
WITHDRAWN
(Jun 1, 2026)
PHASE1, PHASE2 A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Jun 1, 2026)
PHASE1 A Study of KITE-363 in Participants With Refractory Autoimmune Diseases Kite, A Gilead Company NA
ENROLLING BY INVITATION
(Jun 1, 2026)
PHASE1 A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases Nanjing Legend Biotech Co. NA
TERMINATED
(Jun 1, 2026)
PHASE1 TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies St. Jude Children's Research Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE1 Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer George Washington University NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC Anocca AB NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents Children's Cancer Group, China NA
RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL AstraZeneca NA
RECRUITING
(Jun 1, 2026)
PHASE3 Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial SWOG Cancer Research Network NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Arkansas Children's Hospital Research Institute NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas City of Hope Medical Center NA
RECRUITING
(Jun 1, 2026)
PHASE1 CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma Thomas Martin, MD NA
SUSPENDED
(Jun 1, 2026)
PHASE1 A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Jun 1, 2026)
PHASE2 Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1 Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. Chinese PLA General Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant Stanford University NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer Hebei Medical University Fourth Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment SWOG Cancer Research Network NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL Ruijin Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer Beijing Biotech NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer Beijing Biotech NA
RECRUITING
(Jun 1, 2026)
PHASE1 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Joal Beane NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma East Metropolitan Health Service, Australia NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases Fred Hutchinson Cancer Center NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia iCell Gene Therapeutics NA
RECRUITING
(Jun 1, 2026)
PHASE1 A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) BeBetter Med Inc NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Medical University of South Carolina NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies National Cancer Institute (NCI) NA
RECRUITING
(May 5, 2026)
PHASE1 Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease Children's Oncology Group NA
COMPLETED
(May 1, 2026)
PHASE2 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma National Cancer Institute (NCI) NA
COMPLETED
(May 1, 2026)
PHASE3 Mature B-Cell Lymphoma And Leukemia Study III St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Children's Oncology Group NA
COMPLETED
(May 1, 2026)
PHASE3 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Fred Hutchinson Cancer Center NA
COMPLETED
(May 1, 2026)
PHASE2 A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors SynerGene Therapeutics, Inc. NA
SUSPENDED
(May 1, 2026)
PHASE1 Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders Washington University School of Medicine NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. Dana-Farber Cancer Institute NA
RECRUITING
(May 1, 2026)
PHASE1 A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Hoffmann-La Roche NA
COMPLETED
(May 1, 2026)
PHASE3 A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Fred Hutchinson Cancer Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 National Hospital Organization Nagoya Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Fred Hutchinson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE1 LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma Udai Kammula NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Adjuvant Palbociclib in Elderly Patients With Breast Cancer European Organisation for Research and Treatment of Cancer - EORTC NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors Immatics US, Inc. NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients National Cancer Institute (NCI) NA
TERMINATED
(May 1, 2026)
PHASE1, PHASE2 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers Udai Kammula NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center NA
TERMINATED
(May 1, 2026)
PHASE1, PHASE2 PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Udai Kammula NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Kara Lynn Davis NA
COMPLETED
(May 1, 2026)
PHASE1 Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Allogene Therapeutics NA
COMPLETED
(May 1, 2026)
PHASE1 Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Fred Hutchinson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) Cabaletta Bio NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) Incyte Biosciences Japan GK NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma Children's Oncology Group NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk Ruijin Hospital NA
RECRUITING
(May 1, 2026)
PHASE3 TriPRIL CAR T Cells in Multiple Myeloma Marcela V. Maus, M.D.,Ph.D. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma Medical College of Wisconsin NA
COMPLETED
(May 1, 2026)
PHASE2 Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Stanford University NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer SOLTI Breast Cancer Research Group NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Sumithira Vasu NA
RECRUITING
(May 1, 2026)
PHASE1 Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia University of Washington NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients St. Jude Children's Research Hospital NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer Valo Therapeutics Oy NA
RECRUITING
(May 1, 2026)
PHASE1 Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC Queen Mary University of London NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer University of Southern California NA
RECRUITING
(May 1, 2026)
PHASE1 Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression Huazhong University of Science and Technology NA
RECRUITING
(May 1, 2026)
PHASE2 Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) Washington University School of Medicine NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy M.D. Anderson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells UNC Lineberger Comprehensive Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE1 A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease Fate Therapeutics NA
RECRUITING
(May 1, 2026)
PHASE1 A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL Chinese PLA General Hospital NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma The First Affiliated Hospital of Soochow University NA
RECRUITING
(May 1, 2026)
PHASE2 Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors Stanford University NA
RECRUITING
(May 1, 2026)
PHASE1 A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) Nkarta, Inc. NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors M.D. Anderson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) Incyte Corporation NA
RECRUITING
(May 1, 2026)
PHASE3 Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer NEC Bio B.V NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma Juan P. Alderuccio, MD NA
RECRUITING
(May 1, 2026)
PHASE1 A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) Nkarta, Inc. NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia St. Jude Children's Research Hospital NA
RECRUITING
(May 1, 2026)
PHASE1 Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL Peking University People's Hospital NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies University of Kansas Medical Center NA
RECRUITING
(May 1, 2026)
PHASE1 NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma Centre Hospitalier Universitaire Vaudois NA
RECRUITING
(May 1, 2026)
PHASE1 A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) Celgene NA
RECRUITING
(May 1, 2026)
PHASE3 Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) Jennifer Amengual NA
RECRUITING
(May 1, 2026)
PHASE2 A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease M.D. Anderson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors Beijing DCTY Biotech Co.,Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation City of Hope Medical Center NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia Institute of Hematology & Blood Diseases Hospital, China NA
WITHDRAWN
(May 1, 2026)
PHASE1, PHASE2 Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis Xijing Hospital NA
RECRUITING
(May 1, 2026)
PHASE1 Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer Beijing Biotech NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors Beijing Biotech NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer Beijing Biotech NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT Masonic Cancer Center, University of Minnesota NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial. Swiss Cancer Institute NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL Ruijin Hospital NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis Qifeng Zhang NA
RECRUITING
(May 1, 2026)
PHASE2 Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma Beijing Biotech NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Universal STAR-T Cell Injection in R/R Autoimmune Diseases. Jian Zhu NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET) Hospital Universitari Vall d'Hebron Research Institute NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes The First Affiliated Hospital with Nanjing Medical University NA
RECRUITING
(May 1, 2026)
PHASE2 Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma Kure Cells, INC NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL Ruijin Hospital NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer Shanghai Zhongshan Hospital NA
RECRUITING
(May 1, 2026)
PHASE1 Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML Peking University People's Hospital NA
RECRUITING
(May 1, 2026)
PHASE1 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 Beijing Biotech NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC Beijing Biotech NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM) Zhongshan Hospital (Xiamen), Fudan University NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma Beijing Biotech NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). French Innovative Leukemia Organisation NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma Beijing Biotech NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma Beijing Biotech NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). AstraZeneca NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies National Cancer Institute (NCI) NA
RECRUITING
(Apr 3, 2026)
PHASE1 Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Alliance for Clinical Trials in Oncology NA
COMPLETED
(Apr 1, 2026)
PHASE2 Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma Centre Antoine Lacassagne NA
COMPLETED
(Apr 1, 2026)
PHASE2 Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer Centre Antoine Lacassagne NA
COMPLETED
(Apr 1, 2026)
PHASE1 Haploidentical PBMC Transplant for Severe Congenital Anemias National Heart, Lung, and Blood Institute (NHLBI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children University of Birmingham NA
COMPLETED
(Apr 1, 2026)
PHASE2 Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies National Cancer Institute (NCI) NA
COMPLETED
(Apr 1, 2026)
PHASE1 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Kite, A Gilead Company NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer M.D. Anderson Cancer Center NA
COMPLETED
(Apr 1, 2026)
PHASE2 Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Northside Hospital, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant Washington University School of Medicine NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease National Heart, Lung, and Blood Institute (NHLBI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma National Heart, Lung, and Blood Institute (NHLBI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma Sun Yat-sen University NA
COMPLETED
(Apr 1, 2026)
PHASE1 A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) University of Birmingham NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL Chipscreen Biosciences, Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE3 GM-CSF With Post-Transplant Cyclophosphamide Northside Hospital, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer Providence Health & Services NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) Autolus Limited NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Providence Health & Services NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer Iovance Biotherapeutics, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE2 CAR-T Cells for HIV Infection Steven Deeks NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. Cancer Trials Ireland NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Methods of T Cell Depletion Trial (MoTD) University of Birmingham NA
RECRUITING
(Apr 1, 2026)
PHASE2 Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer Providence Health & Services NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Nkarta, Inc. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants Janssen Research & Development, LLC NA
COMPLETED
(Apr 1, 2026)
PHASE1 Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia Christian Buske NA
RECRUITING
(Apr 1, 2026)
PHASE2 Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia Alliance for Clinical Trials in Oncology NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Providence Health & Services NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 ITIL-306 in Advanced Solid Tumors Instil Bio NA
TERMINATED
(Apr 1, 2026)
PHASE1 Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas David Wald NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma Mayo Clinic NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors Grit Biotechnology NA
TERMINATED
(Apr 1, 2026)
PHASE1 Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer Xijing Hospital NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma Kite, A Gilead Company NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors Grit Biotechnology NA
TERMINATED
(Apr 1, 2026)
PHASE1, PHASE2 Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma Lyell Immunopharma, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 CAR T-cell Therapy in Patients With Renal Dysfunction Northside Hospital, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma University College, London NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma USWM, LLC (dba US WorldMeds) NA
COMPLETED
(Apr 1, 2026)
PHASE2 Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE2 UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy University of Alabama at Birmingham NA
RECRUITING
(Apr 1, 2026)
PHASE1 Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) University Health Network, Toronto NA
RECRUITING
(Apr 1, 2026)
PHASE2 Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma University of Kansas Medical Center NA
COMPLETED
(Apr 1, 2026)
PHASE2 Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Apr 1, 2026)
PHASE2 Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) M.D. Anderson Cancer Center NA
RECRUITING
(Apr 1, 2026)
PHASE1 A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors Shanghai NK Cell Technology Co., LTD NA
RECRUITING
(Apr 1, 2026)
PHASE1 Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide Northside Hospital, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma University of Washington NA
RECRUITING
(Apr 1, 2026)
PHASE2 Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial Mayo Clinic NA
WITHDRAWN
(Apr 1, 2026)
PHASE2 FMD and Neoadjuvant Chemo-immunotherapy in TNBC Sun Yat-sen University NA
RECRUITING
(Apr 1, 2026)
PHASE2 MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Masonic Cancer Center, University of Minnesota NA
RECRUITING
(Apr 1, 2026)
PHASE2 Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) Dizal Pharmaceuticals NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors Beijing Biotech NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus Beijing Biotech NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Beijing Biotech NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Tongji Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE1 Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma Shanghai Jiao Tong University School of Medicine NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma Shanghai Jiao Tong University School of Medicine NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL Sun Yat-sen University NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1 Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment Fundación Neumologica Colombiana NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) iCell Gene Therapeutics NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma Beijing Biotech NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer Beijing Biotech NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia The First Affiliated Hospital of Soochow University NA
RECRUITING
(Apr 1, 2026)
PHASE2 Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) National Taiwan University Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies Shenzhen University General Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia City of Hope Medical Center NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Hackensack Meridian Health NA
COMPLETED
(Mar 1, 2026)
PHASE2 Reduced Intensity Haploidentical BMT for High Risk Solid Tumors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
RECRUITING
(Mar 1, 2026)
PHASE2 Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study) University Hospital, Rouen NA
COMPLETED
(Mar 1, 2026)
PHASE3 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas University of Chicago NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 BNHL-2015 for Children or Adolescents in China Children's Cancer Group, China NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2, PHASE3 Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) Kite, A Gilead Company NA
COMPLETED
(Mar 1, 2026)
PHASE2 LBL-2016 for Children or Adolescents in China Children's Cancer Group, China NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) Medical College of Wisconsin NA
COMPLETED
(Mar 1, 2026)
PHASE2 PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia medac GmbH NA
TERMINATED
(Mar 1, 2026)
PHASE2 Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors M.D. Anderson Cancer Center NA
TERMINATED
(Mar 1, 2026)
PHASE1 Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation M.D. Anderson Cancer Center NA
TERMINATED
(Mar 1, 2026)
PHASE2 US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia ExCellThera inc. NA
COMPLETED
(Mar 1, 2026)
PHASE2 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Anusha Kalbasi NA
RECRUITING
(Mar 1, 2026)
PHASE1 CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL Children's Cancer Group, China NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors Baylor College of Medicine NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse Fudan University NA
RECRUITING
(Mar 1, 2026)
PHASE2 Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Kite, A Gilead Company NA
TERMINATED
(Mar 1, 2026)
PHASE2 CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) H. Lee Moffitt Cancer Center and Research Institute NA
RECRUITING
(Mar 1, 2026)
PHASE1 De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis Medical College of Wisconsin NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Mar 1, 2026)
PHASE1 CAR- PRISM (PRecision Intervention Smoldering Myeloma) Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Marcela V. Maus, M.D.,Ph.D. NA
RECRUITING
(Mar 1, 2026)
PHASE1 Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus. Chulalongkorn University NA
COMPLETED
(Mar 1, 2026)
PHASE1 Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC H. Lee Moffitt Cancer Center and Research Institute NA
RECRUITING
(Mar 1, 2026)
PHASE1 A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma Juno Therapeutics, Inc., a Bristol-Myers Squibb Company NA
WITHDRAWN
(Mar 1, 2026)
PHASE3 MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Mayo Clinic NA
RECRUITING
(Mar 1, 2026)
PHASE1 Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus Beijing GoBroad Hospital NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function Washington University School of Medicine NA
RECRUITING
(Mar 1, 2026)
PHASE1 Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma Children's Oncology Group NA
RECRUITING
(Mar 1, 2026)
PHASE3 Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases Beijing GoBroad Hospital NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation Shanghai Jiao Tong University School of Medicine NA
RECRUITING
(Mar 1, 2026)
PHASE3 KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors Corregene Biotechnology Co., Ltd NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia St. Jude Children's Research Hospital NA
RECRUITING
(Mar 1, 2026)
PHASE2 Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma City of Hope Medical Center NA
RECRUITING
(Mar 1, 2026)
PHASE2 DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) Dizal Pharmaceuticals NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Obe-cel in Refractory Progressive Forms of Multiple Sclerosis Autolus Limited NA
RECRUITING
(Mar 1, 2026)
PHASE1 A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer Xijing Hospital NA
COMPLETED
(Mar 1, 2026)
PHASE2 Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies Hackensack Meridian Health NA
RECRUITING
(Mar 1, 2026)
PHASE2 Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells Baylor College of Medicine NA
RECRUITING
(Mar 1, 2026)
PHASE1 Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd NA
WITHDRAWN
(Mar 1, 2026)
PHASE1 T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor Zhejiang University NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia Fujian Medical University NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1 Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1 Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL Ou Bai, MD/PHD NA
RECRUITING
(Mar 1, 2026)
PHASE2 Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation The First Affiliated Hospital of Soochow University NA
RECRUITING
(Mar 1, 2026)
PHASE2 IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia The First Hospital of Jilin University NA
RECRUITING
(Mar 1, 2026)
PHASE2 Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma Nanjing IASO Biotechnology Co., Ltd. NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors Beijing Biotech NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 
